🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Post #ASCO25 thoughts on the DESTINY-Breast09 trial: T-DXd + pertuzumab extended mPFS to 40.7 months in 1st-line HER2+ metastatic breast cancer (THP: 26.9 months, HR: 0.56). The absolute difference of 13.8 months is a remarkable result! This is a turning point that shifts the

🚨 #ASCO2025 Highlight! Prof Francois Duhoux on: ✅ NRG-BR003, NEOSTAR, ABCSG 45 ✅ DAWN-A & TRADE: CDK4/6 insights ✅ WINPRO: progesterone symptom effect 🎥 Watch now medimix.be/onco/asco-2025/ #MediMix #BreastCancer #TNBC #CDK46

🧠 Head & Neck Highlight from #ASCO2025! Dr Willem Lybaert on: 🔹 Cemiplimab vs pembrolizumab in cutaneous SCC 🔹 Immunotherapy/ADC breakthroughs in NPC 🔹 HER2, AR, and triplet therapy in rare H&N tumours 🎥 Watch now bit.ly/4mLvOXR #MediMix #HeadNeckCancer #Oncology

Sicilia, Italy 🎥 lucatriptico | IG

And it got USFDA approval today. It is better strategy than post op nivo alone as probably neo adjuvant IO does the job . Will I like to read full paper published? Yes . U.S. FDA is really fast now a days 🙂

merck.com/news/fda-appro…

Practical HCC treatment algorithm guiding choices from early-stage to systemic disease. More than a flowchart. OncoAlert Oncology Brothers

The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report When it comes to breast cancer, it's important to consider the opinions of Italian oncologists👇 sciencedirect.com/science/articl…

🗣️Head & Neck Highlight from #ASCO2025! Dr Willem Lybaert on #HNSCC: ✔️ KEYNOTE-689: +20 mo EFS w/ neoadj pembro ✔️ NIVOPOSTOP: DFS gain in resected high-risk ✔️ Tumour vaccine = 100% 2y DFS + strong CD8+ ✔️ Ficerafusp + pembro: 54% ORR, 20 mo OS 🎥 Watch now

Overcoming resistance to CDK4/6 inhibitors in hormone receptor positive, HER2 negative breast cancer: Innovative combinations and emerging strategies cancertreatmentreviews.com/article/S0305-…

Excellent work and important addition to the literature of malignant insulinoma. The short summary is, PRRT works! Very similar results to what we recently reported... erc.bioscientifica.com/view/journals/…?

I just posted highly valuable guidelines on MEN1, checked my e-mail and found this... Update in surveillance for VHL. If you are interested in the NET as a manifestation of MEN1, there is a good chance you might be interested in VHL too... aacrjournals.org/clincancerres/…

🎯 Top Sessions to Watch at #ESMOGI25 🔥 From practice-changing data to paradigm debates 👇 🔵 Late Breakers: 1️⃣ MATTERHORN (LBA4) – Durva+FLOT: EFS & PROs in G/GEJ 2️⃣ PANOVA-3 (LBA3) – TTFields: QoL & pain in LAPC 3️⃣ TALENTACE (LBA2) – Atezo/Bev+TACE in HCC: Phase 3 results 🚀

The New MEN1 guidelines just released! Excellent guidance for the daily practice 🏆

🚨Neo and adjuvant pembrolizumab for patients with resectable head and neck squamous cell carcinoma (KEYNOTE689) is now published in NEJM 💥Great step forward in the field Awaiting OS in next interim analyses Will NIVOPOSTOP be approved by FDA as well? U.S. FDA What would be

🔊🔊 Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors 🙌🏼 A new treatment option for ALL NET patients!! 👏🏼 ⁦Grupo GETNE⁩ ⁦NET- ESPAÑA⁩ ⁦NET Research Foundation⁩ ipsen.com/press-releases…

📢 Great news for patients with advanced neuroendocrine tumors: positive CHMP opinion for Cabometyx® after prior treatment. Another step forward in the management of ALL NETs! 👏🏼 Grupo GETNE NET- ESPAÑA NET Research Foundation #NETs #Oncology

A first-in-class EGFR-directed KRAS G12V selective inhibitor Cancer Cell doi.org/10.1016/j.ccel… 👉EFTX-G12V selectively targets KRAS G12V while sparing wild-type KRAS 👉Activity in lung, colon, & PDAC cancer models 🧐 Very interesting MOA, KRAS is becoming draggable ESMO - Eur. Oncology

Press release 👉🏼Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer | Exelixis, Inc. ir.exelixis.com/news-releases/…

🚨 New paper out We compared atezolizumab + bevacizumab vs STRIDE (tremelimumab + durvalumab) in advanced #HCC using real-world data from #TriNetX. 🎯 No OS difference → both are valid 1L options. 👩‍⚕️ Better survival with atezo+bev in females. link.springer.com/article/10.100…